Strategic partnerships Sygnature Discovery is actively expanding collaboration through external platforms and partners, such as a DEL screening collaboration with X-Chem, signaling openness to integrated solutions and joint go-to-market opportunities that could benefit potential partners or clients seeking end-to-end discovery programs.

Advanced capabilities The company has invested in cutting-edge platforms and assays, including Next-Generation antibody drug conjugates eBook, KV7.2/7.3 channel assay, recombinant Factor C endotoxin testing, and ExpiCHO-S mammalian expression, enabling conversations about innovative services and differentiated offerings for complex drug discovery projects.

Leadership and capacity With a global team of 700+ scientists across Europe and North America and leadership appointments in in vivo pharmacology, Sygnature demonstrates depth in bioscience expertise and project execution capacity, suggesting readiness to scale collaborations and take on larger programs for pharma and biotech clients.

Proven outcomes A track record of 200+ active projects, 60+ advanced candidates, and 200+ patents filed over 20 years indicates a mature, outcomes-driven CRO, suitable for prospective customers prioritizing reliability, confidentiality, and a high likelihood of rapid progression to candidate nomination.

Industry relevance Core therapeutic focuses include oncology, inflammation and immunology, neuroscience, metabolic and fibrotic diseases, aligning with high-demand areas in pharma/biotech pipelines and creating targeted opportunities to pitch integrated discovery partnerships to companies with needs in these sectors.